Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vanguard Total International Stock Index Fund ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vanguard Total International Stock Index Fund ETF trades at $83.12 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 64.9× Globus Medical Inc. Class A Common Stock's market cap, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard Total International Stock Index Fund ETF for 56 Days on average.
| GMED | VXUS | |
|---|---|---|
Market Cap | $10.25B | $665.70B |
Volume | 1,108,124 | 4,659,186 |
Sector | Health | Sector/Thematic |
52-Week High | $96.82 | $88.41 |
52-Week Low | $58.33 | $72.19 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VXUS trades at $84.54 with minimal daily movement (+0.12%). Technical indicators show bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. The ETF provides broad international stock exposure outside the U.S., offering diversification benefits. Recent institutional activity shows growing interest, with firms like QRG Capital increasing positions by 97.8% in Q2 2026 (SEC filing, September 2026).
VXUS offers cost-effective international diversification but faces currency and geopolitical risks. Current bearish technicals suggest near-term pressure, while long-term prospects depend on global market performance versus U.S. equities. The upcoming $0.16 dividend in September 2026 provides income, but foreign tax credit limitations in IRAs may reduce net returns for some investors (24/7 Wall Street, August 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
